Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Breast Neoplasms 102Carcinoma, Non-Small-Cell Lung 94Multiple Myeloma 85Prostatic Neoplasms 74Neoplasms 57Colorectal Neoplasms 57Leukemia, Myeloid, Acute 56Lymphoma 50Lung Neoplasms 43Squamous Cell Carcinoma of Head and Neck 42Neoplasm Metastasis 38Pancreatic Neoplasms 36Melanoma 35Ovarian Neoplasms 34Lymphoma, Non-Hodgkin 34Lymphoma, Large B-Cell, Diffuse 34Carcinoma, Hepatocellular 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Urinary Bladder Neoplasms 30Head and Neck Neoplasms 30Carcinoma, Renal Cell 28Myelodysplastic Syndromes 27Leukemia, Lymphocytic, Chronic, B-Cell 27Hodgkin Disease 27Triple Negative Breast Neoplasms 26Sarcoma 26Hematologic Neoplasms 26Recurrence 25Glioma 25Endometrial Neoplasms 23

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoid Tumor × 30 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡